NanoString Technologies and MD Anderson to Collaborate on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NanoString Technologies and MD Anderson to Collaborate on Development of Multi-Omic Assays Simultaneously Profiling Gene and Protein Expression

HOUSTON and SEATTLE, April 1, 2015 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and NanoString Technologies, Inc. (Nasdaq: NSTG ), a provider of life science tools for translational research and molecular diagnostic products, today announced a multi-year collaboration to accelerate the development and adoption of a revolutionary new type of assay based on NanoString's nCounter ® Analysis System. The collaboration will involve the development of "multi-omic" assays, which simultaneously profile both gene and protein expression, with a primary focus on identifying important biomarkers in the burgeoning field of immuno-oncology as well as extending programs for targeting therapeutics.

"These types of assays are designed to provide a powerful tool for comprehensively probing tumor biology. These assays have the potential to capture the biology needed to optimize the use of new cancer therapeutics, especially in the dynamic field of immuno-oncology, where matching patients with the right combination of therapies is critical, initially in clinical trials and then in patient treatment," said Gordon Mills, M.D., Ph.D., chair of Systems Biology at MD Anderson. Mills is co-director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy and will lead the joint collaboration effort.

NanoString intends to introduce new research panels for the simultaneous measurement of gene and protein expression, with the beta launch of the first panel planned for the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, April 18-22, 2015. With the addition of this proteomic capability, the nCounter Analysis System will hold a unique distinction of having capabilities for concurrent genomic and proteomic analysis. NanoString's nCounter Analysis System is an automated and easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high precision multiplexed assays across a number of important research applications. NanoString's nCounter technology uses color-coded molecular barcodes that can hybridize directly to many different types of target molecules. nCounter assays are enzyme-free and capable of generating high-quality results from challenging sample types, including FFPE tissue.

"Our current PanCancer Pathway and Immune Profiling gene expression panels offer researchers powerful assays for understanding the tug-of-war between the drivers of tumor growth and the immune system's response," said Brad Gray, President and Chief Executive Officer of NanoString Technologies. "In collaboration with experts at MD Anderson, we will be adding a new proteomic dimension to these assays, and aiming to demonstrate their potential to inform drug development and selection."

Key objectives of the collaboration include: development of new multi-omic assays and signatures that profile key oncology disease pathways and immune response from tumor tissue; incorporation of these multi-omic assays into select clinical studies being run at MD Anderson to predict response and monitor response to cancer immuno-therapies and targeted therapies, both as single agents and combinations; and identification of clinically actionable proteomic markers across multiple tumor types. Under the terms of the agreement, NanoString is granted rights to research and diagnostic content developed within the scope of the collaboration.

At the 2015 AACR Annual Meeting in Philadelphia, Pennsylvania, Joe Beechem, Ph.D., Senior Vice President of Research & Development at NanoString Technologies, will provide an introduction to NanoString's nCounter-based multi-omic assays. The presentation is titled "Simultaneous multi-omic measurement of gene fusions, mRNA and proteins at 800-plex using single molecule optical barcodes" and is scheduled for Monday, April 20 at 10:00 AM Eastern time.

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in over 600 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

For more information, please visit www.nanostring.com .

The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For the past 25 years, MD Anderson has ranked as one of the nation's top two cancer centers in U.S. News & World Report's annual "Best Hospitals" survey. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Get MD Anderson News Via RSS

Follow MDAnderson News on Twitter

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the scientific and medical potential of our multi-omic technology to simultaneously profile gene and protein expression, and its ability to optimize the use of new cancer therapeutics in the field of immuno-oncology. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

NanoString Contact: Leigh Salvo of Westwicke Partners 415-513-1281 MD Anderson Contact: Ron Gilmore 713-745-1898

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 70

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 25

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 69

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 147

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 91

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 118

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading

Top 5 Most Recently Viewed Articles

Uncovering Surveillance Pricing: Consumer Watchdog's New Insights

Updated Category News Views 124

Understanding Surveillance Pricing in Today's Market As we continue to navigate the digital landscape, a new and concerning practice has emerged within the retail and e-commerce sectors — surveillance pricing. This strategy allows corporations to charge different prices to consumers for the same item based on their personal data and online behavior, as highlighted by...

Continue Reading
Understanding Voting Rights and Capital at Albion Technology

Updated Category News Views 136

Total Voting Rights and Capital Overview Albion Technology & General VCT PLC In accordance with Disclosure Guidance and Transparency Rule 5.6.1, we at Albion Technology & General VCT PLC are providing key insights into our voting rights and capital structure. Issued Share Capital Details As of the recent update, the issued share capital and voting rights of the Company...

Continue Reading
Hisense Unveils Cutting-Edge Smart Home Solutions at IFA

Updated Category News Views 130

Transforming Everyday Living with Hisense Smart Technology Leading the way in home technology, Hisense recently showcased a range of innovative smart home solutions designed to enhance daily living at the IFA 2024 trade show. As a prominent name in consumer electronics, Hisense is committed to elevating the smart living experience for users worldwide. Hisense's Dedication...

Continue Reading
Jeffs’ Brands Enters Strategic Agreement for Security Tech Expansion

Updated Category News Views 296

Exploring New Horizons: Jeffs’ Brands' Non-Binding MOU The 3D, AI-Powered Technology Screens 25,000 People Per Hour—Without Stopping Them In an exciting development for Jeffs' Brands Ltd (“Jeffs’ Brands” or the “Company”) (NASDAQ: JFBR, JFBRW), a leading data-driven e-commerce firm leveraging the Amazon Marketplace, the company has announced its wholly owned...

Continue Reading
Garmin and Global Researchers Unveil Groundbreaking Happiness Study

Updated Category News Views 175

Introduction to the Health and Happiness Study Garmin, known for its innovative technology, has embarked on an exciting journey in collaboration with researchers from prestigious institutions aimed at understanding the intricate relationship between technology, happiness, and wellbeing. This Health and Happiness Study represents a significant step forward in the quest to...

Continue Reading